ArticleAdvanced healthcare materials2025
Geometric Adjustment of T Cell-Sensitive Nanorobots for Enhanced Stability.
Article in Advanced healthcare materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Application of Micro/Nanorobots in Cancer Therapy.Micromachines · 2026Review
- Development of Dendritic Cell Membrane-Coated Nanoparticles for Antigen-Specific T-Cell Engagement.ACS biomaterials science & engineering · 2025Article
- Geometric Adjustment of T Cell-Sensitive Nanorobots for Enhanced Stability.Advanced healthcare materials · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Personalized dendritic cell (DC) based vaccines offer promising immunotherapeutic approaches for cancers and infectious diseases by leveraging living DCs to stimulate a patient's immune system through interactions with T cells. However, conventional DC-based vaccines face significant challenges, including limited stability and short storage lifespan of the living cells. To overcome these limitations, smart artificial nanorobots, termed nano-bone marrow dendritic cell (BMDC)-originated T cell activators (nano-BOTs) are developed by incorporating 1-dimensional (1D) nanoparticles to enhance stability and activation efficacy. The use of 1D nanoparticles enables precise modulation of the geometric properties, resulting in significantly improved interactions with effector T cells. This innovative approach addresses the inherent limitations of traditional DC-based vaccines and amplifies their ability to activate effector T cells. The advanced nanorobots exhibit exceptional stability and therapeutic potential, representing a transformative step toward personalized DC-based vaccines in future biological therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.